Weight regain after bariatric surgery is common. Semaglutide observational evidence shows 10–15% additional body weight loss. Coordination with bariatric surgery team is essential.
Why this matters
Bariatric surgery produces ~25–35% mean weight loss. Significant regain over 5–10 years is common. GLP-1 therapy is increasingly used to address regain short of revision surgery.
The evidence
Observational studies show 10–15% additional body weight loss with semaglutide post-bariatric. Randomized trial data are limited but increasing. Mechanism remains intact post-surgery; absorption considerations differ between sleeve and RYGB.
Sleeve gastrectomy
Most absorption pathways intact. GLP-1 therapy typically follows standard dosing.
RYGB
Altered anatomy may affect oral medication absorption. Sema and tirz are subcutaneous (not oral) so this is less relevant. Oral semaglutide (Rybelsus) is more affected.
Coordination
Coordinate with your bariatric surgery team. They know your specific anatomy and surgical history. Don't initiate GLP-1 without their awareness.
Nutritional considerations
Post-bariatric patients are at higher risk of micronutrient deficiency. Reduced food intake on GLP-1 compounds this. Continue post-bariatric vitamin and mineral supplementation; monitor labs more closely.